A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Inclusion Criteria:

• Have Type 2 Diabetes

• Have HbA1c ≥7.0% (53 mmol/mol) to ≤9.5% (80 mmol/mol) despite diet and exercisetreatment, as determined by the central laboratory at screening.

• Are naïve to insulin therapy except for gestational diabetes or ≤14 days use foracute treatment and have not used any oral or injectable antihyperglycemicmedications during the 90 days preceding screening or between screening andrandomization.

• Are of stable weight (±5%) for at least 90 days prior to screening and agree to notinitiate an intensive diet or exercise program during the study with the intent ofreducing body weight other than the lifestyle and/or dietary measures for diabetestreatment.

• Have a body mass index (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening.

Exclusion Criteria:

• Have Type 1 Diabetes

• Have a history of ketoacidosis or hyperosmolar state or coma within the last 6months prior to screening, or between screening and randomization.

• Currently receiving or planning to receive treatment for diabetic retinopathy and/ormacular edema

• Have New York Heart Association functional classification IV congestive heartfailure.

• Have acute or chronic pancreatitis